What is RSP?
RSP Systems is at the forefront of developing non-invasive glucose monitoring technology, aiming to democratize glucose measurement for a global population. Their flagship product, GlucoBeam Smart, represents a paradigm shift by enabling users to track glucose levels without the need for painful skin punctures. The company's primary focus is on individuals managing diabetes and those at risk of elevated blood sugar levels, with a mission to enhance the accessibility of vital health data. RSP Systems is dedicated to establishing a new benchmark in glucose monitoring through cutting-edge technology and a robust team.
How much funding has RSP raised?
RSP has raised a total of $19.8M across 3 funding rounds:
Series A
$5.1M
Unspecified
$2.7M
Series B
$12M
Series A (2016): $5.1M, investors not publicly disclosed
Unspecified (2016): $2.7M led by Horizon 2020
Series B (2018): $12M supported by Trumpf Venture
Key Investors in RSP
Trumpf Venture
Trumpf Venture is associated with TRUMPF, a global technology company specializing in machine tools, laser technology, and electronics, suggesting a focus on advanced manufacturing and technological innovation.
Horizon 2020
Horizon 2020, operating within the Government sector, likely supports research and innovation initiatives, indicating an interest in groundbreaking technologies like RSP's non-invasive monitoring.
What's next for RSP?
The substantial enterprise-level funding and recent strategic investment provide RSP Systems with the necessary resources to accelerate its product development and market penetration. This capital infusion is expected to fuel further innovation in non-invasive monitoring solutions, potentially expanding the company's reach to new demographics and therapeutic areas. The company's trajectory suggests a strong focus on scaling operations and solidifying its position as a leader in accessible health technology, with future growth likely centered on clinical validation and broader commercialization efforts.
See full RSP company page
